C
Canary Speech
Artificial intelligence software for the healthcare industry to detect neurological diseases through voice analysis
About Canary Speech
Canary Speech was co-founded by Henry O'Connell and Jeff Adams. O'Connell has a background of over 25 years in the medical device industry, while Adams is a recognized figure in speech and language technology.
Read full description
The company has developed a patented vocal biomarker technology that uses artificial intelligence to analyze speech patterns and detect various health conditions. This technology is designed to be language-agnostic and can be used on any device with a microphone, including smartphones and computers. The analysis is done in near real-time, providing immediate results from as little as 20 seconds of speech.
Canary Speech's primary market is the healthcare industry, where its technology can be used to screen for cognitive and behavioral conditions such as Alzheimer's, dementia, depression, and anxiety. The company's business model is based on providing its platform to healthcare providers, who can then use it to assess and monitor their patients. The technology is non-invasive and can be used to conduct analysis anytime and anywhere, making it a convenient and stress-free option for patients.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Provo, United States
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 88.2/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Core AI, Health Diagnostics, Biotech and Pharma, Generative AI
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning, Nanotech
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Canary Speech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2024 | $13M | $52M | Hackensack Meridian Health · Smk · Cortes capital · Sorenson | ↗ |
| EARLY VC✓Equity / VC | Jun 2023 | $0 | — | Hackensack Meridian Health | ↗ |
Growth signals
Latest recorded traffic for Canary Speech is 13K monthly website visits, up 150% over the last three months. Canary Speech's team grew 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Hackensack Meridian Health- CCCortes capital
Smk
Sorenson
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Canary Speech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Canary Speech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.